Related references
Note: Only part of the references are listed.Bortezomib attenuates murine collagen-induced arthritis
S-W Lee et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Long term treatment of rheumatoid arthritis with rituximab
Roberto Caporali et al.
AUTOIMMUNITY REVIEWS (2009)
Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders
Jorge Castillo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Inhibition of osteoblastic bone formation by nuclear factor-κB
Jia Chang et al.
NATURE MEDICINE (2009)
Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review
Andrea Rubbert-Roth et al.
ARTHRITIS RESEARCH & THERAPY (2009)
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
P. Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Overexpression of Toll-like Receptors 3 and 4 in Synovial Tissue From Patients With Early Rheumatoid Arthritis Toll-like Receptor Expression in Early and Longstanding Arthritis
Caroline Ospelt et al.
ARTHRITIS AND RHEUMATISM (2008)
Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis
Shahla Abdollahi-Roodsaz et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Biologic treatment of rheumatoid arthritis and the risk of malignancy - Analyses from a large US observational study
Frederick Wolfe et al.
ARTHRITIS AND RHEUMATISM (2007)
Myeloma bone-disease and proteasome inhibition therapies
Evangelos Terpos et al.
BLOOD (2007)
An essential role of NF-κB in the tumor-like phenotype of arthritic synoviocytes
Xiangli Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial
Daina Vanags et al.
LANCET (2006)
Proteasome inhibitor bortezomib for the treatment of multiple myeloma
M. Cavo
LEUKEMIA (2006)
Identification of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of rheumatoid arthritis
MF Roelofs et al.
JOURNAL OF IMMUNOLOGY (2006)
Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis
A. Finckh et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials
T Bongartz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines
B Blanco et al.
BLOOD (2006)
Pathogen recognition and innate immunity
S Akira et al.
CELL (2006)
The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
FC Breedveld et al.
ARTHRITIS AND RHEUMATISM (2006)
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma
JR Berenson et al.
CANCER (2005)
The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages
L Schaefer et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Drug therapy - Therapeutic strategies for rheumatoid arthritis
JR O'Dell
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Increased synovial tissue NF-κB1 expression at sites adjacent to the cartilage-pannus junction in rheumatoid arthritis
MJ Benito et al.
ARTHRITIS AND RHEUMATISM (2004)
Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib
K Sun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Development of the proteasome inhihitor Veleade((TM)) (Bortezomib)
J Adams et al.
CANCER INVESTIGATION (2004)
Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-κB-dependent process
Y Dai et al.
ONCOGENE (2003)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Evolving concepts of rheumatoid arthritis
GS Firestein
NATURE (2003)
Expression and regulation of toll-like receptor 2 in rheumatoid arthritis synovium
R Seibl et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
NF-κB regulation in the immune system
QT Li et al.
NATURE REVIEWS IMMUNOLOGY (2002)
Mechanisms of disease: Cytokine pathways and joint inflammation in rheumatoid arthritis.
EHS Choy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
JM Bathon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Distinct roles for the NF-κB1 (p50) and c-Rel transcription factors in inflammatory arthritis
IK Campbell et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
Fibroblast biology - Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis
T Pap et al.
ARTHRITIS RESEARCH (2000)
Share Paper
